Clinician-scientist specializing in translational immunotherapy for hematologic malignancies, with a primary focus on CAR-T cell therapy for relapsed/refractory acute leukemias. Her work has led to several first-in-field clinical advances, integrates early-phase clinical trials with mechanistic studies on relapse, antigen escape, and CAR-T persistence, contributing to international guidelines and high-impact publications.

PhD, Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2018-2021

Tenure-track Associate Professor, Chinese Academy of Medical Sciences and Peking Union Medical College, 2026-

Associate Chief Physician; Director, Proof-of-Concept (POC) Ward, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, 2026-

PRINCIPAL HONORS, AWARDS:

2021    Top Ten Research Advances in Chinese Hematology

2024    Top Ten Research Advances in Chinese Hematology

MAJOR NATIONAL LEADERSHIP POSITIONS, SOCIETIES AND BOARDS:

2026–2028    Founding Editorial Advisory Board Member, Pediatric and Young Adult Cancer (PAYAC), an American Cancer Society journal published by Wiley

SELECTED PUBLICATIONS:

1.Pan J，et al.. Allogeneic CD5-specific CAR-T therapy for r/r T-ALL: a phase 1 trial. Nat Med. 2024; 31(1): 126-136

2.Pan J，et al.. Donor-derived CD7 CAR T cells for pediatric and adult r/r T-ALL/LBL: a phase 2 trial. Blood 2025; Dec 4; 146(23): 2745-2757.

3.Pan J，et al.. Sequential CD19 and CD22 CAR-T therapy for childhood r/r B-ALL. Lancet Oncology 2023; 24(11): 1229-1241

4.Tan Y, Shan LL, Zhao LP, Deng BP, Ling ZJ, Zhang YL, Peng SX, Xu JL, Duan JJ, Wang ZL, Yu XJ, Zheng QL, Xu XW, Tian ZL, Zhang YB, Zhang JC, Chang·Alex H., Feng X, Pan J*. Long-term follow-up of donor-derived CD7 CAR-T therapy in T-ALL. J Hematol Oncol 2023; 16(1): 34-49

5.Pan J，et al.. Donor-derived CD7 CAR T cells for T-ALL: first-in-human phase I trial. J Clin Oncol 2021; 39(30): 3340-3351